Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease

被引:3
|
作者
Tajima, Naoyuki
Nagashima, Satoru
Uematsu, Toshihiko
Torii, Hideki
Tajima, Masami
Hishida, Akira
Naganuma, Hideo
机构
[1] Sankyo Co Ltd, Clin Pharmacol & Biostat Dept, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[3] Shitoro Clin, Hamamatsu, Shizuoka 4328067, Japan
[4] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan
关键词
prediction; pharmacokinetics; hemodialysis; end-stage renal disease (ESRD); antibiotic;
D O I
10.1248/bpb.29.1454
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel and convenient method to predict the pharmacokinetics of several kinds of antibiotic agents in patients with end-stage renal disease (ESRD) was examined based on the in vitro extraction ratios and pharmacokinetic parameters in healthy volunteers. The dializability of 17 antibiotic agents in 4% human serum albumin solution were determined using a high-performance hemodialytic membrane for clinical use. We assumed that the off-hemodialysis clearance approximated the non-renal clearance, while the on-hemodialysis clearance was considered to be sum of the off-hemodialysis clearance and the hemodialytic clearance. The estimated on- and off-hemodialysis clearances were compared with the ones observed in ESRD patients. In order to confirm the method prospectively, an in vivo pharmacokinetic study was performed in dogs with mercury chloride-induced experimental renal failure. The in vitro extraction ratios of 9 beta-lactams were broadly ranged from 10.9 to 75.6% depending on their physicochemical properties. In contrast, those of the other antibiotics were consistent with their chemical classes: 60.5-63.2% for fluoroquinolone, 48.8-51.1% for aminoglycoside and 18.7-25.6% for glycopeptide. Both the estimated on- and off-hemodialysis clearances of the 17 antibiotics coincided well with the observed values in the literature, regardless of their physicochemical and pharmacokinetic properties. The validity and applicability of this method to three cefems, cefmetazole, cefotaxime and cefoperazone, was prospectively confirmed in the animal study. In conclusion, this new method enables the prediction of the on- and off-hemodialysis clearances of several kinds of antibiotics in ESRD patients from minimal information of their pharmacokinetics in healthy subjects and their in vitro dializability.
引用
收藏
页码:1454 / 1459
页数:6
相关论文
共 50 条
  • [1] Pharmacokinetics of Intravenous Delafloxacin in Patients With End-Stage Renal Disease
    Hoover, Randall
    Alcorn, Harry, Jr.
    Lawrence, Laura
    Paulson, Susan K.
    Quintas, Megan
    Cammarata, Sue K.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (07) : 913 - 919
  • [2] Pharmacokinetics of rosiglitazone in patients with end-stage renal disease
    Thompson-Culkin, K
    Zussman, B
    Miller, AK
    Freed, MI
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2002, 30 (04) : 391 - 399
  • [3] THE PHARMACOKINETICS OF AMINOGUANIDINE IN END-STAGE RENAL-DISEASE PATIENTS ON HEMODIALYSIS
    FOOTE, EF
    LOOK, ZM
    GILES, P
    KEANE, WF
    HALSTENSON, CE
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (03) : 420 - 425
  • [4] THE EFFECT OF HEMODIALYSIS ON THE PHARMACOKINETICS OF TENOXICAM IN PATIENTS WITH END-STAGE RENAL-DISEASE
    ALGHAMDI, MS
    ALMOHANNA, FA
    ALMUSTAFA, ZH
    ALSAEED, IS
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (02) : 197 - 199
  • [5] Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
    Juliette Thariat
    Marie-Christine Etienne-Grimaldi
    Vincent Launay-Vacher
    Arturo Soto-Matos
    Carlos Fernandez-Teruel
    Thomas Ghafari
    Pierre-Yves Marcy
    Gérard Milano
    Nicole Renée
    Lauris Gastaud
    Antoine Thyss
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1363 - 1367
  • [6] Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
    Thariat, Juliette
    Etienne-Grimaldi, Marie-Christine
    Launay-Vacher, Vincent
    Soto-Matos, Arturo
    Fernandez-Teruel, Carlos
    Ghafari, Thomas
    Marcy, Pierre-Yves
    Milano, Gerard
    Renee, Nicole
    Gastaud, Lauris
    Thyss, Antoine
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1363 - 1367
  • [7] PHARMACOKINETICS OF ZIDOVUDINE IN END-STAGE RENAL-DISEASE - INFLUENCE OF HEMODIALYSIS
    PACHON, J
    CISNEROS, JM
    CASTILLO, JR
    GARCIAPESQUERA, F
    CANAS, E
    VICIANA, P
    AIDS, 1992, 6 (08) : 827 - 830
  • [8] Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease
    Pastores, Gregory M.
    Boyd, Ellen
    Crandall, Kerry
    Whelan, Alison
    Piersall, Linda
    Barnett, Natalie
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (07) : 1920 - 1925
  • [9] Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease
    Kimmel, PL
    Lew, SQ
    Li, PP
    Gordon, AM
    Straw, J
    BLOOD PURIFICATION, 1995, 13 (06) : 340 - 346
  • [10] Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis
    Pai, Sudhakar M.
    Chaikin, Philip
    Berg, Jolene Kay
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (10) : 1379 - 1383